<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314245</url>
  </required_header>
  <id_info>
    <org_study_id>AnchorDx-BC004</org_study_id>
    <nct_id>NCT04314245</nct_id>
  </id_info>
  <brief_title>Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma</brief_title>
  <official_title>Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnchorDx Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital &amp; Clinical Medical College of Chengdu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AnchorDx Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate the performance characteristics(sensitivity and specificity) of
      AnchorDx's urine DNA methylation/somatic mutation profiling assay for detecting urothelial
      carcinoma compared to pathology in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study that involves 11 centers in China and 1200 participants. The
      assay analyzes the DNA methylation/somatic mutation profiles of bladder cancer-specific
      biomarkers non-invasively using urine specimens collected before invasive
      diagnosis/treatment. The performance characteristics(sensitivity and specificity) of the
      assay for detection of urothelial carcinoma is evaluated in comparison to pathology or
      cystoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Performance for the detection of urothelial carcinoma</measure>
    <time_frame>1 Years</time_frame>
    <description>The efficacy of the urine DNA methylation/somatic mutation profiling assay for the detection of urothelial carcinoma comparing with pathologic diagnosis, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (-LR) and accuracy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity in different pathological stages and histologic grades of urothelial carcinoma</measure>
    <time_frame>1 Years</time_frame>
    <description>Sensitivity and specificity of urine DNA methylation/somatic mutation profiling assay in different pathological stages and histologic grades of urothelial carcinoma.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Urothelial carcinoma group</arm_group_label>
    <description>Subjects who diagnosed with incident or recurrent urothelial carcinoma (including bladder/ureter/renal pelvis) by surgical pathology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>interference group</arm_group_label>
    <description>Subjects who diagnosed with incident or recurrent bladder cancer other than urothelial carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer) by surgical pathology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Subjects who clinically diagnosed with benign disease of the urinary system, such as Urinary calculi, urinary tract infection (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers group</arm_group_label>
    <description>Volunteers who have a normal routine urine test / ultrasound examination of the urinary system and do not carry suspected tumors of other organs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Pathology</intervention_name>
    <description>Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.</description>
    <arm_group_label>Urothelial carcinoma group</arm_group_label>
    <arm_group_label>interference group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Clinical Diagnosis</intervention_name>
    <description>Routine clinical diagnosis and treatment of benign disease of the urinary system</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Clinical diagnosis</intervention_name>
    <description>Routine urine test and imaging diagnostic techniques, such as B-ultrasound.</description>
    <arm_group_label>Healthy volunteers group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay</intervention_name>
    <description>A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Healthy volunteers group</arm_group_label>
    <arm_group_label>Urothelial carcinoma group</arm_group_label>
    <arm_group_label>interference group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects consisted of four types : 1) Patients with urothelial carcinoma; 2) Patients with
        the other bladder cancer (including bladder squamous cell carcinoma/bladder
        adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer); 3) Patients
        with benign disease of the urinary system, such as Urinary calculi, urinary tract infection
        (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis; 4) Healthy
        volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Urothelial carcinoma group:

               -  Any male or female patient aged 18 or older.

               -  Able to provide urine specimen (100ml for both first void and non-first-void
                  urine) before treatments.

               -  Diagnosed with incident or recurrent urothelial carcinoma (including
                  bladder/ureter/renal pelvis) by surgery.

          2. interference group:

               -  Any male or female patient aged 18 or older.

               -  Able to provide urine specimen (100ml for both first void and non-first-void
                  urine) before treatments.

               -  Diagnosed with incident or recurrent bladder cancer other than urothelial
                  carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other
                  bladder-related cancers/prostate cancer/rectal cancer) by surgery.

          3. Control group:

               -  Any male or female patient aged 18 or older.

               -  Able to provide urine specimen (100ml for both first void and non-first-void
                  urine) before treatments.

               -  Diagnosed with urinary disease such as Urinary calculi, urinary tract infection
                  (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.
                  All enrollee are able to provide legally effective informed consent.

          4. Healthy volunteers group:

               -  Any male or female patient aged 18 or older.

               -  Able to provide urine specimen (100ml for both first void and non-first-void
                  urine) before physical examination.

        exclusion criteria:

          1. Urothelial carcinoma/Interference group/Control group

               -  Has had diagnosed with other cancers.

               -  Patients diagnosed with non-urological cancer.

               -  Failed to provide a written informed consent.

          2. Healthy volunteers group:

               -  Volunteers with abnormal test results of urine analysis or urological ultrasound
                  test.

               -  Volunteers sceptical of cancers from non-urological origin in a normal results of
                  urine analysis or urological ultrasound.

               -  Failed to provide legally effective informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian HUANG, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu CHEN, MD</last_name>
    <phone>+86-13430306339</phone>
    <email>chenxu-joshua@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xia LI</last_name>
    <phone>+86-15902059556</phone>
    <email>xia_li@anchordx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu CHEN, MD</last_name>
      <phone>+86-13430306339</phone>
      <email>chenx457@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jian HUANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xu CHEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Urine</keyword>
  <keyword>DNA methylation</keyword>
  <keyword>Somatic mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

